China Isotope & Radiation Corporation (1763.HK)

HKD 10.4

(-2.07%)

EBITDA Summary of China Isotope & Radiation Corporation

  • China Isotope & Radiation Corporation's latest annual EBITDA in 2023 was 1.22 Billion CNY , up 7.73% from previous year.
  • China Isotope & Radiation Corporation's latest quarterly EBITDA in 2024 Q2 was 526.2 Million CNY , down 0.0% from previous quarter.
  • China Isotope & Radiation Corporation reported an annual EBITDA of 1.05 Billion CNY in 2022, up 16.95% from previous year.
  • China Isotope & Radiation Corporation reported an annual EBITDA of 901.43 Million CNY in 2021, up 25.65% from previous year.
  • China Isotope & Radiation Corporation reported a quarterly EBITDA of N/A for 2023 FY, up 7.73% from previous quarter.
  • China Isotope & Radiation Corporation reported a quarterly EBITDA of 528.03 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of China Isotope & Radiation Corporation (2023 - 2015)

Historical Annual EBITDA of China Isotope & Radiation Corporation (2023 - 2015)

Year EBITDA EBITDA Growth
2023 1.22 Billion CNY 7.73%
2022 1.05 Billion CNY 16.95%
2021 901.43 Million CNY 25.65%
2020 717.43 Million CNY -6.86%
2019 770.3 Million CNY -0.54%
2018 774.44 Million CNY 22.15%
2017 632.84 Million CNY 7.68%
2016 591.18 Million CNY 7.4%
2015 548.59 Million CNY 0.0%

Peer EBITDA Comparison of China Isotope & Radiation Corporation

Name EBITDA EBITDA Difference
Vincent Medical Holdings Limited 104.43 Million HKD -1071.03%